26 results on '"Kim, Nam Doo"'
Search Results
2. Data from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
3. Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
4. Supplementary Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
5. Supplementary Methods from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
6. Supplementary Table S1 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
7. Supplementary Table S1 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
8. Supplementary Data from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
9. Supplementary Figure S1 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
10. Data from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
11. Supplementary Figure Legends from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
12. Supplementary Figure S2 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
13. Supplementary Figure S2 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
14. Supplementary Materials and Methods from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
15. Supplementary Table S2 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
16. Supplementary Methods from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
17. Supplementary Figure Legends from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
18. Supplementary Table S2 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
19. Supplementary Figure S1 from Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
20. Supplementary Materials and Methods from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
21. Abstract LB521: Antitumor activity of potent RAF inhibitors in solid tumors with activated RAS-RAF axis
22. Abstract P2-13-15: VRN101396, a brain-permeable HER2 inhibitor, shows the anti-tumor activity in preclinical HER2-positive cancer models
23. Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
24. Abstract P234: ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetrant properties and enhanced potency in preclinical studies of HER2-positive breast cancer
25. Abstract B002: Discovery of selective and potent EGFR kinase inhibitors for exon20 insertion mutations
26. Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.